Loading...
Market
What will be Trodelvy's market position in ES-SCLC treatment by end of 2025?
2
Resolution / Starting Odds
Leading • 25%
Second • 25%
Third • 25%
Lower • 25%
Market analysis reports from reputable industry analysts
Story
FDA Grants Breakthrough Therapy Designation to Trodelvy for ES-SCLC Treatment
Dec 18, 2024, 12:06 PM
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for the second-line treatment of extensive-stage small cell lung cancer (ES-SCLC). This designation is intended to expedite the development and review of drugs that demonstrate substantial improvement over existing therapies for serious or life-threatening conditions. Trodelvy, developed by Gilead Sciences, has shown promise in addressing the needs of patients with ES-SCLC who have limited treatment options. The FDA's decision highlights the potential of Trodelvy to improve outcomes for this patient population.
View original story
Similar markets
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%
Europe • 25%
Asia • 25%
South America • 25%
Africa • 25%
Optune Lua with PD-1/PD-L1 inhibitors • 25%
Sunvozertinib • 25%
Durvalumab with chemotherapy • 25%
Other • 25%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Leader • 25%
Top 3 • 25%
Top 5 • 25%
Outside Top 5 • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%